13.07

2.83% -0.38

Replimune Group Inc (REPL)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$13.45

Offen:

$13.69

24-Stunden-Volumen:

1.31M

Relative Volume:

0.31

Marktkapitalisierung:

$1.23B

Einnahmen:

Nettoeinkommen (Verlust:

$-313.94M

KGV:

-3.7279

EPS:

-3.506

Netto-Cashflow:

$-284.57M

1W Leistung:

+5.74%

1M Leistung:

-18.21%

6M Leistung:

+55.41%

1J Leistung:

+181.08%

1-Tages-Spanne:

$12.80

$13.83

1-Wochen-Bereich:

$12.07

$13.83

52-Wochen-Spanne:

$1.50

$16.33

Replimune Group Inc Stock (REPL) Company Profile

Firmenname

Replimune Group Inc

Sektor

Healthcare (1064)

Branche

Biotechnology (595)

Telefon

(781) 222-9600

Adresse

500 UNICORN PARK, WOBURN, MA

Mitarbeiter

465

Twitter

@Replimune

Nächster Verdiensttermin

2026-11-05

Neueste SEC-Einreichungen

REPL's Discussions on Twitter

Compare REPL vs VRTX, MRNA, REGN, ARGX, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
REPL Replimune Group Inc	13.07	1.16B	0	-313.94M	-284.57M	-3.506
VRTX Vertex Pharmaceuticals Inc	504.73	127.93B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	190.01	79.40B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	735.20	81.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.21	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	206.64	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Replimune Group Inc Stock (REPL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-13	Herabstufung	BMO Capital Markets	Market Perform → Underperform
2026-04-13	Herabstufung	H.C. Wainwright	Buy → Sell
2026-04-13	Herabstufung	JP Morgan	Neutral → Underweight
2026-04-13	Herabstufung	Jefferies	Buy → Hold
2026-04-13	Herabstufung	Leerink Partners	Outperform → Market Perform
2026-04-13	Herabstufung	Wedbush	Outperform → Neutral
2026-04-10	Herabstufung	Piper Sandler	Overweight → Neutral
2025-11-03	Hochstufung	BMO Capital Markets	Underperform → Market Perform
2025-10-27	Hochstufung	H.C. Wainwright	Neutral → Buy
2025-10-20	Hochstufung	JP Morgan	Underweight → Neutral
2025-10-20	Hochstufung	Leerink Partners	Market Perform → Outperform
2025-10-20	Hochstufung	Piper Sandler	Neutral → Overweight
2025-10-20	Hochstufung	Wedbush	Neutral → Outperform
2025-09-19	Herabstufung	JP Morgan	Neutral → Underweight
2025-07-30	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2025-07-23	Herabstufung	BMO Capital Markets	Outperform → Underperform
2025-07-23	Herabstufung	Barclays	Overweight → Equal Weight
2025-07-23	Herabstufung	H.C. Wainwright	Buy → Neutral
2025-07-22	Herabstufung	JP Morgan	Overweight → Neutral
2025-07-22	Herabstufung	Leerink Partners	Outperform → Market Perform
2025-07-22	Herabstufung	Piper Sandler	Overweight → Neutral
2025-07-22	Herabstufung	Wedbush	Outperform → Neutral
2025-06-20	Eingeleitet	Cantor Fitzgerald	Overweight
2024-08-28	Eingeleitet	ROTH MKM	Buy
2023-04-17	Fortgesetzt	Piper Sandler	Overweight
2021-11-19	Eingeleitet	Piper Sandler	Overweight
2021-10-15	Fortgesetzt	BTIG Research	Buy
2020-11-17	Eingeleitet	BTIG Research	Buy
2020-11-02	Eingeleitet	Jefferies	Buy
2020-10-15	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-07-01	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-05-05	Eingeleitet	Barclays	Overweight
2019-09-04	Eingeleitet	ROTH Capital	Buy
2019-07-23	Eingeleitet	Chardan Capital Markets	Buy
2019-07-12	Hochstufung	JP Morgan	Neutral → Overweight
2019-07-08	Eingeleitet	H.C. Wainwright	Buy
2019-04-25	Eingeleitet	Wedbush	Outperform
2019-01-23	Herabstufung	JP Morgan	Overweight → Neutral
2018-08-14	Eingeleitet	JP Morgan	Overweight
2018-08-14	Eingeleitet	Leerink Partners	Outperform

Alle ansehen

Replimune Group Inc Aktie (REPL) Neueste Nachrichten

Oct 01, 2026

Replimune launches melanoma therapy in US market By Investing.com - Investing.com Canada

Oct 01, 2026

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma - Yahoo! Finance Canada

Oct 01, 2026

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, - GlobeNewswire

Oct 01, 2026

Replimune CEO and CFO sued for allegedly mislea... - Pluang

Oct 01, 2026

SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026REPL - TradingView

Oct 01, 2026

Sep 30, 2026

REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits

Sep 30, 2026

Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) InvestorsLead Plaintiff Deadline on October 5, 2026 - ACCESS Newswire

Sep 30, 2026

REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities LawsuitContact Levi & Korsinsky - PR Newswire

Sep 30, 2026

Sep 29, 2026

Portnoy Law Firm Announces Class Action on Behalf of Replimune Group, Inc. Investors - GlobeNewswire

Sep 29, 2026

Sep 28, 2026

REPL Investor Alert: Replimune Group, Inc. Securities Class Action NoticeContact Levi & Korsinsky - GlobeNewswire

Sep 28, 2026

Sep 27, 2026

Understanding the Setup: (REPL) and Scalable Risk - Stock Traders Daily

Sep 27, 2026

Sep 26, 2026

Replimune’s Melanoma FDA Decision Pending: This Analyst Sees 40% Upside, ‘High Conviction’ For Approval - Stocktwits

Sep 26, 2026

Why Is REPL Stock Soaring 127% After Hours Today? - Stocktwits

Sep 26, 2026

Sep 25, 2026

Lost Money on Replimune Group, Inc. (REPL)? Contact Levi & Korsinsky to Join Class Action Before October 5, 2026 - ACCESS Newswire

Sep 25, 2026

REPL STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Sep 25, 2026

Securities Lawsuit Alert: Replimune Group, Inc. (REPL)Contact Levi & Korsinsky Before October 5, 2026 - ACCESS Newswire

Sep 25, 2026

REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review

Sep 25, 2026

Class Action Filed Against Replimune Group, Inc. (REPL) Over Securities ViolationsContact Levi & Korsinsky Today - ACCESS Newswire

Sep 25, 2026

Sep 24, 2026

Class action lawsuit filed against Replimune af... - Pluang

Sep 24, 2026

ETFs Investing in Replimune Group, Inc. Stocks - TradingView

Sep 24, 2026

Securities Class Action Lawsuit Filed Against Replimune Group, Inc. (REPL)Levi & Korsinsky Represents Shareholders - ACCESS Newswire

Sep 24, 2026